STOCK TITAN

Insider Notice: ALEC Restricted Stock Sale Planned (76,446 shares)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Alector, Inc. (ALEC) submitted a Form 144 reporting a proposed sale of 76,446 common shares with an aggregate market value of $152,892.00, against 101,212,329 shares outstanding. The filing states the shares were acquired as restricted stock on 03/01/2023 and lists an approximate sale date of 08/08/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The notice also discloses a prior sale of 16,488 shares on 06/02/2025 for gross proceeds of $22,065.89. The signer represents there is no undisclosed material adverse information and includes standard Rule 144 attestations.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider plans a small, compliant sale of restricted shares; size is immaterial to capitalization.

The Form 144 notifies the market of a proposed sale of 76,446 restricted shares valued at $152,892, representing roughly 0.08% of the reported 101.2 million shares outstanding. From a market-impact standpoint this is immaterial to equity capitalization and likely will not affect trading liquidity or valuation. The filing names Morgan Stanley Smith Barney as broker and provides an approximate sale date, which supports regulatory transparency but does not imply material company-level change.

TL;DR: Filing demonstrates routine insider compliance with Rule 144; disclosures are standard and include prior recent sale.

The notice documents acquisition as restricted stock on 03/01/2023 and confirms the required attestation that no undisclosed material adverse information exists. The inclusion of a recent sale on 06/02/2025 for 16,488 shares shows prior deleveraging by the reporting person. These elements indicate standard adherence to disclosure obligations rather than signaling governance concerns or material events requiring investor action.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Alector

NASDAQ:ALEC

View ALEC Stock Overview

ALEC Rankings

ALEC Latest News

ALEC Latest SEC Filings

ALEC Stock Data

233.97M
95.26M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
SOUTH SAN FRANCISCO